Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 1997

View Archived Issues

Company Profile: Sepracor

EntreMed reports positive preclinical results using Endostatin

Maillard reaction inhibitors from Kissei

Takeda discloses new series of prolactin secretion inhibitors

Antiangina agents in development at Sankyo

Water-soluble taxanes reported in patent literature

Preclinical profile of Co-102862 presented at neuroscience congress

Behavioral effects of neurosteroid elucidated in nonhuman primate model

Anticonvulsant activity demonstrated for adenosine kinase inhibitor

Cypress Bioscience: Q3 1997 highlights

Combination malaria vaccine enters phase I

FDA approves ANDA for generic clozapine

Reduced PSF expression associated with development of vascular lesions

HCV protease inhibitors to be designed and developed by BMS and Arris

Compounds for 5-HT-mediated disorders from Astra

CoCensys/Acea reveal new AMPA receptor antagonists/positive modulators

VEGF receptor tyrosine kinase inhibitors under development at Zeneca

Neurogen patents new dopamine receptor subtype-specific ligands

Mechanism of renoprotective effects of ACE inhibitors in diabetic nephropathy

Kissei accelerates overseas development

ID Vaccine acquires rights to new AIDS vaccine

Yamanouchi advances overseas development

Valsartan approved in Canada

Intermittent therapy with 5-HT reuptake inhibitor effective for dysphoric PMS

Pfizer discontinues collaboration with Megabios

Amarillo reports positive phase II data in Sjogren's syndrome trial

Novo Nordisk licenses tiagabine to Sanofi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...